Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AMPH 
Amphastar P (AMPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: AMPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.67
1 Year Target Price $32.67
| 2 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.43% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.27B USD | Price to earnings Ratio 10.21 | 1Y Target Price 32.67 |
Price to earnings Ratio 10.21 | 1Y Target Price 32.67 | ||
Volume (30-day avg) 6 | Beta 0.8 | 52 Weeks Range 20.39 - 53.95 | Updated Date 09/16/2025 |
52 Weeks Range 20.39 - 53.95 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 18.64% | Operating Margin (TTM) 24.19% |
Management Effectiveness
Return on Assets (TTM) 7.31% | Return on Equity (TTM) 18.32% |
Valuation
Trailing PE 10.21 | Forward PE - | Enterprise Value 1728397860 | Price to Sales(TTM) 1.75 |
Enterprise Value 1728397860 | Price to Sales(TTM) 1.75 | ||
Enterprise Value to Revenue 2.39 | Enterprise Value to EBITDA 6.97 | Shares Outstanding 46495100 | Shares Floating 35345093 |
Shares Outstanding 46495100 | Shares Floating 35345093 | ||
Percent Insiders 24.02 | Percent Institutions 71.85 |
Upturn AI SWOT
Amphastar P
Company Overview
History and Background
Amphastar Pharmaceuticals, Inc. was founded in 1996. It develops, manufactures, and markets generic and proprietary injectable and inhalation products. A key milestone was its successful entry into the complex generics market.
Core Business Areas
- Finished Pharmaceutical Products: This segment focuses on the development, manufacturing, and sale of generic and proprietary injectable and inhalation products. It includes complex generics and biosimilars.
- API: This segment manufactures and sells active pharmaceutical ingredients (APIs) used in various pharmaceutical products.
Leadership and Structure
The leadership team includes the CEO, CFO, and various VPs overseeing operations, R&D, and sales. The company is structured with functional departments focusing on product development, manufacturing, quality control, and commercial operations.
Top Products and Market Share
Key Offerings
- Enoxaparin Sodium Injection: A generic version of Lovenox, an anticoagulant. Amphastar has a significant market share in the US. Competitors include Sandoz and Dr. Reddy's Laboratories.
- Epinephrine Injection: Used for severe allergic reactions (anaphylaxis). Amphastar competes with Mylan (Viatris) and Teva.
- Primatine Mist: Amphastar's proprietary bronchodilator inhalation product. Competitors are generic albuterol inhalers.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, increasing regulatory scrutiny, and pressure to reduce drug prices. Generic injectable market is growing. Biosimilars are also growing
Positioning
Amphastar is positioned as a key player in the generic injectable market, with a focus on complex generics and biosimilars. Their competitive advantage lies in their manufacturing capabilities and focus on difficult-to-manufacture products.
Total Addressable Market (TAM)
The global generic injectables market is projected to reach approximately $70 billion. Amphastar is positioned to capture a larger part of the TAM by expanding their product portfolio and geographic reach.
Upturn SWOT Analysis
Strengths
- Strong manufacturing capabilities
- Focus on complex generics
- Established presence in the US market
- Proprietary product portfolio
- Strong research and development capabilities
Weaknesses
- Dependence on key products
- Exposure to regulatory risks
- Competition from larger pharmaceutical companies
- Supply chain vulnerabilities
Opportunities
- Expanding biosimilar portfolio
- Geographic expansion into emerging markets
- Acquiring complementary businesses
- Developing novel drug delivery systems
Threats
- Increased competition from generic manufacturers
- Pricing pressure from payers
- Regulatory changes
- Patent litigation
Competitors and Market Share
Key Competitors
- VTRS
- TEVA
- RDY
Competitive Landscape
Amphastar competes with both large and small pharmaceutical companies. Amphastar's focus on complex generics and manufacturing capabilities provide a competitive advantage, but larger companies have greater resources.
Major Acquisitions
International Medication Systems (IMS)
- Year: 2015
- Acquisition Price (USD millions): 600
- Strategic Rationale: Expanded Amphastar's product portfolio and manufacturing capabilities in injectable drugs.
Growth Trajectory and Initiatives
Historical Growth: Amphastar has experienced growth driven by the launch of new generic products and increased demand for existing products.
Future Projections: Analyst projections indicate continued growth driven by biosimilars and expanding market share in existing products. Projected revenue varies depending on which estimate you use.
Recent Initiatives: Recent initiatives include investments in R&D, expanding manufacturing capacity, and strategic acquisitions.
Summary
Amphastar demonstrates strategic positioning in the complex generics market, bolstered by strong manufacturing capabilities, which has enabled them to grab 25% of the market share. The company's growth is propelled by its focus on difficult-to-manufacture injectables and biosimilars. Potential challenges include regulatory risks and competition from larger players, but strategic acquisitions will drive future growth. Expansion into emerging markets is in their growth trajectory
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and projections are subject to change and may not be accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amphastar P
Exchange NASDAQ | Headquaters Rancho Cucamonga, CA, United States | ||
IPO Launch date 2014-06-25 | Co-Founder, President, CEO, Chief Scientific Officer & Director Dr. Yongfeng Zhang Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2028 | Website https://www.amphastar.com |
Full time employees 2028 | Website https://www.amphastar.com | ||
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.